David A. Siegel Relmada Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 288,000 shares of RLMD stock, worth $172,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares

288,000

Previous 198,900 44.8%

Holding current value

$172,800

Previous $103,000 25.24%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.26 - $0.47 $23,166 - $41,877	89,100 Added 44.8%	288,000 $77,000
Q4 2024 Feb 14, 2025	SELL	$0.35 - $3.65 $15,259 - $159,140	-43,600 Reduced 17.98%	198,900 $103,000
Q3 2024 Nov 14, 2024	SELL	$2.3 - $4.36 $114,999 - $218,000	-50,000 Reduced 17.09%	242,500 $785,000
Q2 2024 Aug 14, 2024	SELL	$2.93 - $4.94 $98,741 - $166,478	-33,700 Reduced 10.33%	292,500 $877,000
Q1 2024 May 15, 2024	SELL	$3.1 - $6.8 $6,510 - $14,280	-2,100 Reduced 0.64%	326,200 $1.52 Million
Q4 2023 Feb 14, 2024	BUY	$2.45 - $4.22 $401,555 - $691,658	163,900 Added 99.7%	328,300 $1.36 Million
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $201,624 - $308,127	-81,300 Reduced 33.09%	164,400 $493,000
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $248,418 - $396,126	-111,900 Reduced 31.29%	245,700 $604,000
Q1 2023 May 15, 2023	BUY	$2.24 - $4.76 $77,280 - $164,220	34,500 Added 10.68%	357,600 $808,000
Q4 2022 Feb 14, 2023	BUY	$2.17 - $35.84 $654,472 - $10.8 Million	301,600 Added 1402.79%	323,100 $1.13 Million
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $393,450 - $795,930	21,500 New	21,500 $796,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

6.43M

Call Options Held

Put Options Held

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $17.2M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account